Oragenics, Inc. (NYSEAMERICAN:OGEN) Sees Large Growth in Short Interest

Oragenics, Inc. (NYSEAMERICAN:OGEN) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 139,273 shares, an increase of 303.6% from the November 30th total of 34,508 shares. Based on an average daily volume of 114,186 shares, the days-to-cover ratio is presently 1.2 days. Currently, 3.7% of the shares of the stock are sold short. Currently, 3.7% of the shares of the stock are sold short. Based on an average daily volume of 114,186 shares, the days-to-cover ratio is presently 1.2 days.

Oragenics Price Performance

OGEN stock traded up $0.02 during mid-day trading on Friday, reaching $0.86. 76,791 shares of the company traded hands, compared to its average volume of 84,531. The company has a fifty day moving average price of $1.03 and a 200-day moving average price of $1.48. Oragenics has a 52-week low of $0.82 and a 52-week high of $18.90. The company has a market capitalization of $3.58 million, a P/E ratio of -0.07 and a beta of 0.92.

Oragenics (NYSEAMERICAN:OGEN) last released its quarterly earnings data on Friday, November 7th. The company reported ($1.96) EPS for the quarter.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Bank of America Corp DE grew its position in Oragenics by 7,374.0% during the second quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock worth $59,000 after buying an additional 15,338 shares in the last quarter. Sabby Management LLC bought a new stake in shares of Oragenics during the 3rd quarter valued at about $77,000. Finally, Clear Street LLC bought a new stake in shares of Oragenics during the 2nd quarter valued at about $270,000. 18.71% of the stock is currently owned by hedge funds and other institutional investors.

About Oragenics

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.